SPC
CYTK icon

Sigma Planning Corp’s Cytokinetics CYTK Stock Holding History

Sigma Planning Corp’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-9,700
Closed -$229K – 1081
2020
Q2 		$229K Buy
+9,700
New +$182K 0.01% 887

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Sigma Planning Corp's CYTK Position: Q3 2020 in Review

Sigma Planning Corp sold out of Cytokinetics (CYTK) in Q3 2020, closing a stake of 9,700 shares — an estimated $229K sold.

Sigma Planning Corp first reported a position in CYTK in Q2 2020 and held it in 1 quarter. The position peaked at $229K in Q2 2020. 181 funds tracked by Wall St. Rank hold CYTK as of Q3 2020.

  • Sigma Planning Corp reported no remaining Cytokinetics position as of Q3 2020 after selling out during the quarter.
  • Sigma Planning Corp sold 9,700 Cytokinetics shares in Q3 2020, an estimated $229K.
  • Sigma Planning Corp first reported a position in Cytokinetics in Q2 2020 and held it in 1 quarter.
  • Sigma Planning Corp's Cytokinetics position peaked at $229K in Q2 2020.
  • 181 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2020.

Based on Sigma Planning Corp's 13F filing for Q3 2020, filed 3 Nov 2020.